Daewoong saw the highest growth of 179% in patent filings and 799% in grants in March in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 72% and grants by 74%. GlobalData’s DataBook provides a comprehensive analysis of Daewoong’s patent filings and grants. Buy the databook here.
Daewoong has been focused on protecting inventions in South Korea(KR) with ten publications in Q1 2024
The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 32% filings and 17% grants. The South Korea(KR), Brazil(BR), European Patent Office(EPO), and China(CN) patent Office are among the top ten patent offices where Daewoong is filings its patents. Among the top granted patent authorities, Daewoong has 25% of its grants in Japan(JP), 17% in South Korea(KR) and 17% in European Patent Office(EPO).
F. Hoffmann-La Roche could be the strongest competitor for Daewoong
Patents related to rare diseases and electronic medical record (emr) systems lead Daewoong's portfolio
Daewoong has the highest number of patents in rare diseases followed by, electronic medical record (emr) systems and healthtech. For rare diseases, nearly 29% of patents were filed and no patents were granted in Q1 2024.
Fibrosis related patents lead Daewoong portfolio followed by diabetes, and mos micro (mpu, mcu & dsp)
Daewoong has highest number of patents in fibrosis followed by diabetes, mos micro (mpu, mcu & dsp), healthcare it, and medical imaging information systems.
For comprehensive analysis of Daewoong's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.